ETANERCEPT

Brand name:

• Nepexto®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Rheumatoid arthritis;
• Juvenile idiopathic arthritis;
• Psoriatic arthritis;
• Plaque psoriasis;
• Ankylosing spondylitis.

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (–)

Comment:

--

Submission sponsor:

ALPHAPHARM PTY LTD

Other PBAC consideration:

--

Submission received for:

November 2022 PBAC meeting

Opportunity for consumer comment:

Open 27/07/2022 and close 21/09/2022 (see PBS Website)

PBAC meeting:

Held on 02/11/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

30/10/2024

Lodgement of required documentation:

03/12/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 19/12/2024

Status:

Finalised

Government processes:

Commenced on 17/01/2025

Medicine listed on the PBS:

01/07/2025 (see PBS schedule)

---